您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Reltecimod
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Reltecimod
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Reltecimod图片
CAS NO:1447799-33-8
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
AB-103
产品介绍
Reltecimod (AB-103) 是一种 T 细胞特异性表面糖蛋白 CD28 (TP44) 拮抗剂。Reltecimod对不同的细菌感染、细菌外毒素和内毒素以及电离辐射都有良好的抗性作用。Reltecimod 通过靶向和减弱关键的 CD28/B7-2 共刺激通路来调节炎症反应,而不抑制它。Reltecimod 可用于研究坏死性软组织感染 (NSTIs)。
生物活性

Reltecimod (AB-103) is aT-cell-specific surfaceglycoproteinCD28 (TP44)antagonist. Reltecimod has beneficial effects against differentbacterialinfections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2].

IC50& Target

TP44, Bacteria[1][2]

体内研究
(In Vivo)

Reltecimod (1.25-5 mg/kg; i.v.) increases the survival rate of mice infected with different bacteria[2].

Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration withE. coli018:K1)[2]
Dosage:1.25 or 5 mg/kg
Administration:i.v.; single dosage; at 4 h post infection
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.
Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration withStreptococcus pyogenes)[2]
Dosage:2.5 or 5 mg/kg
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.
Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.
Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2]
Dosage:1.25, 2.5, or 5 mg/kg
Administration:i.v.; single dosage
Result:Increased day 7 survival by up to 100%.
Clinical Trial
分子量

1037.19

Formula

C46H72N10O15S

CAS 号

1447799-33-8

Sequence Shortening

ASPMLVAYDA

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.